FDA Requests Withdrawal of Weight-Loss Drug Belviq From Market

Feb. 13, 2020, 8:18 PM

The FDA cites potential cancer risk for the market withdrawal recommendation for Belviq.

  • Eisai, which markets the drug in the US, has submitted a request to voluntarily withdraw the drug, the FDA says
  • Belviq developer Arena Pharma’s shares are down about 3% after falling as much as 12% on the news
  • NOTE: Jan. 14, FDA Safety Trial Shows Possible Cancer Risk From Eisai’s Belviq

To view the source of this information click here

To contact the reporter on this story:
Polina Noskova in New York at pnoskova@bloomberg.net

To contact the editor responsible for this story:
Angela Moon at hmoon43@bloomberg.net

© ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.